Research_strapline

Are you an:

Don't let the labels put you off!
If you're not an investor, but you want to learn, you can select investor

×

Register for FundCalibre!

We just need to know
if you are an:

Don't let the labels put you off!
If you're not an investor, but you want to learn, you can select investor

×

27 April 2017

US technology index hits 6,000 for the first time


The NASDAQ composite index—which consists of more than 3,000 companies, including the world’s foremost technology and biotech giants such as Apple, Google, Microsoft, Oracle, Amazon, Intel and Amgen—made the headlines this week when it broke the 6,000 mark for the first time.

The index has risen more than 12% since the start of 2017, compared with a rise of 7% for the S&P 500*.

NASDAQ time between milestones

However, as the table below shows, some may say that this new milestone has been a long time coming – the technology bubble at the start of the millennium having taken its toll.

NASDAQ time between milestones

Emotional rather than fundamental importance

Jeremy Gleeson, manager of Elite Rated AXA Framlington Global Technology fund, commented: “The bottom line is that it's just a price level. There’s emotion attached to it because of the perception of it being a milestone, but it doesn’t carry any fundamental importance, as it is not a measure relative to earnings, sales, growth or yield of the underlying companies.

“Valuations are the far more important metric right now and the data shows that technology companies are generally at the more expensive end of their trading range, but not excessively so.

“It's also worth noting that although closely linked to technology and used widely as a benchmark for this sector, the NASDAQ is not a pure tech index. Around 50% is made up of technology stocks, with about 15-20% in healthcare and consumer companies, with the remainder in smaller weightings to other sectors.”

Where to next?

*Source: FE Analytics, 1 Jan 2017 to 27 April 2017, total returns in US dollars.

©2017 FundCalibre Ltd. All Rights Reserved. The information, data, analyses, and opinions contained herein (1) include the proprietary information of FundCalibre, (2) may not be copied or redistributed without prior permission, (3) do not constitute investment advice offered by FundCalibre, (4) are provided solely for informational purposes and therefore are not an offer to buy or sell a security, and (5) are not warranted to be correct, complete, or accurate. FundCalibre, shall not be responsible for any trading decisions, damages, or other losses resulting from, or related to, this information, data, analyses, or opinions or their use.